dobutamine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
dopaminergic agents dopamine derivatives used as cardiac stimulant/antihypertensives/diuretics 937 34368-04-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • dobutamine
  • dobutamine hydrochloride
  • dobutamine HCl
A catecholamine derivative with specificity for BETA-1 ADRENERGIC RECEPTORS. It is commonly used as a cardiotonic agent after CARDIAC SURGERY and during DOBUTAMINE STRESS ECHOCARDIOGRAPHY.
  • Molecular weight: 301.39
  • Formula: C18H23NO3
  • CLOGP: 2.43
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 4
  • TPSA: 72.72
  • ALOGS: -4.34
  • ROTB: 7

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.50 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.13 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
CL (Clearance) 115 mL/min/kg Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
July 18, 1978 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Stress cardiomyopathy 391.82 83.08 57 226 1404 2356398
Drug ineffective 91.18 83.08 40 243 101584 2256218

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Eosinophilic myocarditis 64.25 56.01 9 228 108 1746436
Drug ineffective 63.91 56.01 30 207 63771 1682773
Ventricular fibrillation 62.10 56.01 14 223 2742 1743802

Pharmacologic Action:

SourceCodeDescription
ATC C01CA07 CARDIOVASCULAR SYSTEM
CARDIAC THERAPY
CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
Adrenergic and dopaminergic agents
MeSH PA D018663 Adrenergic Agents
MeSH PA D000322 Adrenergic Agonists
MeSH PA D058665 Adrenergic beta-1 Receptor Agonists
MeSH PA D000318 Adrenergic beta-Agonists
CHEBI has role CHEBI:38147 cardiotonic drug
CHEBI has role CHEBI:35524 sympathomimetic agent
CHEBI has role CHEBI:35522 beta-adrenergic agonist
MeSH PA D002316 Cardiotonic Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D020011 Protective Agents
MeSH PA D013566 Sympathomimetics

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Cardiogenic shock indication 89138009
Decompensated cardiac failure indication 195111005
Organic Cardiac Disease indication
Cardiac Decompensation Post Cardiac Surgery indication
Cardiac Decompensation indication
Ventricular premature beats contraindication 17338001
Myocardial infarction contraindication 22298006 DOID:5844
Hypovolemia contraindication 28560003
Hypertensive disorder contraindication 38341003 DOID:10763
Hypokalemia contraindication 43339004
Atrial fibrillation contraindication 49436004 DOID:0060224
Aortic valve stenosis contraindication 60573004 DOID:1712
Idiopathic hypertrophic subaortic stenosis contraindication 360465008

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.98 acidic
pKa2 10.59 acidic
pKa3 13.49 acidic
pKa4 9.03 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Beta-2 adrenergic receptor GPCR AGONIST EC50 6.20 WOMBAT-PK CHEMBL
Beta-1 adrenergic receptor GPCR AGONIST EC50 5.50 WOMBAT-PK CHEMBL
Sodium-dependent noradrenaline transporter Transporter Ki 6.42 DRUG MATRIX
Alpha-2B adrenergic receptor GPCR Ki 5.87 DRUG MATRIX
D(3) dopamine receptor GPCR Ki 5.77 DRUG MATRIX
Sodium-dependent dopamine transporter Transporter Ki 6.91 DRUG MATRIX
Alpha-1D adrenergic receptor GPCR Ki 7.35 DRUG MATRIX
Epidermal growth factor receptor Kinase IC50 5.26 DRUG MATRIX
Tyrosine-protein kinase Lck Kinase IC50 5.26 DRUG MATRIX
Tyrosine-protein kinase Fyn Kinase IC50 5.40 DRUG MATRIX
Carbonic anhydrase 5A, mitochondrial Enzyme Ki 6.14 CHEMBL
Carbonic anhydrase 2 Enzyme Ki 6.32 CHEMBL
Carbonic anhydrase 14 Enzyme Ki 4.92 CHEMBL
Carbonic anhydrase 7 Enzyme Ki 5.37 CHEMBL
Carbonic anhydrase 12 Enzyme Ki 5.36 CHEMBL
Carbonic anhydrase 9 Enzyme Ki 5.01 CHEMBL
Carbonic anhydrase 4 Enzyme Ki 5.05 CHEMBL
Carbonic anhydrase 1 Enzyme Ki 5.72 CHEMBL
Carbonic anhydrase 5B, mitochondrial Enzyme Ki 6.05 CHEMBL
Carbonic anhydrase 3 Enzyme Ki 5.13 CHEMBL
Carbonic anhydrase 13 Enzyme Ki 5.02 CHEMBL
Carbonic anhydrase 6 Enzyme Ki 5.02 CHEMBL
Catechol O-methyltransferase Enzyme Km 4.30 WOMBAT-PK
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 5.98 DRUG MATRIX
Sodium-dependent serotonin transporter Transporter Ki 6.00 DRUG MATRIX
Arachidonate 15-lipoxygenase Enzyme IC50 6.22 DRUG MATRIX
Alpha-1B adrenergic receptor GPCR Ki 6.73 DRUG MATRIX
Membrane-associated progesterone receptor component 1 Membrane receptor Ki 5.80 DRUG MATRIX
Carbonic anhydrase 15 Enzyme Ki 6.41 CHEMBL
Alpha-1A adrenergic receptor GPCR IC50 6.96 CHEMBL

External reference:

IDSource
D004280 MESH_DESCRIPTOR_UI
4019730 VUID
N0000147822 NUI
C0012963 UMLSCUI
D00632 KEGG_DRUG
0WR771DJXV UNII
49745-95-1 SECONDARY_CAS_RN
3340 INN_ID
26523005 SNOMEDCT_US
3616 RXNORM
387145002 SNOMEDCT_US
d00215 MMSL
4019730 VANDF
000614 NDDF
CHEBI:4670 CHEBI
CHEMBL926 ChEMBL_ID
DB00841 DRUGBANK_ID
CHEMBL1200418 ChEMBL_ID
Y00 PDB_CHEM_ID
535 IUPHAR_LIGAND_ID
36811 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Dobutamine Hydrochloride in Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0338-1073 INJECTION 100 mg INTRAVENOUS NDA 11 sections
Dobutamine Hydrochloride in Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0338-1075 INJECTION 200 mg INTRAVENOUS NDA 11 sections
Dobutamine Hydrochloride in Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0338-1077 INJECTION 400 mg INTRAVENOUS NDA 11 sections
DOBUTAMINE HUMAN PRESCRIPTION DRUG LABEL 1 0409-2025 INJECTION, SOLUTION 12.50 mg INTRAVENOUS ANDA 12 sections
DOBUTAMINE HUMAN PRESCRIPTION DRUG LABEL 1 0409-2344 INJECTION, SOLUTION, CONCENTRATE 12.50 mg INTRAVENOUS ANDA 12 sections
Dobutamine in Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0409-2346 INJECTION, SOLUTION 100 mg INTRAVENOUS NDA 12 sections
Dobutamine in Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0409-2347 INJECTION, SOLUTION 200 mg INTRAVENOUS NDA 12 sections
Dobutamine in Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0409-3724 INJECTION, SOLUTION 400 mg INTRAVENOUS NDA 12 sections
Dobutamine Hydrochloride in Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 50090-4562 INJECTION 400 mg INTRAVENOUS NDA 11 sections
DOBUTAMINE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1330 INJECTION, SOLUTION 200 mg INTRAVENOUS NDA 12 sections
DOBUTAMINE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1337 INJECTION, SOLUTION, CONCENTRATE 12.50 mg INTRAVENOUS ANDA 12 sections
Dobutamine HUMAN PRESCRIPTION DRUG LABEL 1 52584-048 INJECTION, SOLUTION 12.50 mg INTRAVENOUS ANDA 11 sections
Dobutamine HUMAN PRESCRIPTION DRUG LABEL 1 54868-5717 INJECTION, SOLUTION 12.50 mg INTRAVENOUS ANDA 12 sections
Dobutamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 54868-5777 INJECTION, SOLUTION 400 mg INTRAVENOUS NDA 12 sections